Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $7.41 Million - $9.01 Million
-45,200 Reduced 15.95%
238,100 $47 Billion
Q2 2024

Aug 13, 2024

BUY
$154.79 - $180.76 $25.8 Million - $30.2 Million
166,800 Added 143.18%
283,300 $48.6 Billion
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $2.03 Million - $2.31 Million
-12,700 Reduced 9.83%
116,500 $21.2 Billion
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $10.9 Million - $12.3 Million
79,200 Added 158.4%
129,200 $20 Billion
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $5.53 Million - $6.4 Million
-41,400 Reduced 45.3%
50,000 $7.45 Billion
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $6.48 Million - $8.06 Million
48,900 Added 115.06%
91,400 $12.3 Billion
Q1 2023

May 12, 2023

BUY
$144.61 - $166.54 $6.15 Million - $7.08 Million
42,500 New
42,500 $6.77 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Eisler Capital (Us) LLC Portfolio

Follow Eisler Capital (Us) LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eisler Capital (Us) LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eisler Capital (Us) LLC with notifications on news.